PCOS Renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) in Major Medical Consensus

A global medical consensus has officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This significant change, published in The Lancet, results from a decade-long process involving over 22,000 participants, including patients and professionals from six continents. The previous name was deemed misleading as it focused on ovarian cysts, which are actually immature follicles and not present in all cases. The new terminology, PMOS, better reflects the condition's nature as a complex hormonal and metabolic disorder affecting approximately 10-13% of women. The term highlights three key aspects: polyendocrine disturbances, metabolic risks such as type 2 diabetes and cardiovascular disease, and ovarian issues like infertility. Experts argue that this renaming will improve patient care by shifting clinical focus away from solely gynecological symptoms to a broader understanding of the lifelong health risks involved, including mental health and metabolic complications. The decision aims to reduce stigma and ensure comprehensive treatment strategies for those affected.